Literature DB >> 21781997

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Anna P Durbin1, Beth D Kirkpatrick, Kristen K Pierce, Alexander C Schmidt, Stephen S Whitehead.   

Abstract

The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21781997      PMCID： PMC3170437          DOI： 10.1016/j.vaccine.2011.07.023

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  43 in total

1.  A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.

Authors:  J M Troyer; K A Hanley; S S Whitehead; D Strickman; R A Karron; A P Durbin; B R Murphy
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

2.  Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.

Authors:  Kathryn A Hanley; Jay J Lee; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Authors:  A P Durbin; R A Karron; W Sun; D W Vaughn; M J Reynolds; J R Perreault; B Thumar; R Men; C J Lai; W R Elkins; R M Chanock; B R Murphy; S S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2001-11       Impact factor: 2.345

4.  Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus.

Authors:  P M Armstrong; R Rico-Hesse
Journal:  Vector Borne Zoonotic Dis       Date:  2001       Impact factor: 2.133

5.  Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Authors:  J E Blaney; D H Johnson; C Y Firestone; C T Hanson; B R Murphy; S S Whitehead
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks.

Authors:  María G Guzmán; Gustavo Kourí; Luis Valdés; José Bravo; Susana Vázquez; Scott B Halstead
Journal:  Rev Panam Salud Publica       Date:  2002-04

7.  Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

Authors:  D W Vaughn; S Green; S Kalayanarooj; B L Innis; S Nimmannitya; S Suntayakorn; T P Endy; B Raengsakulrach; A L Rothman; F A Ennis; A Nisalak
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells.

Authors:  Joseph E Blaney; Daniel H Johnson; Gracielle G Manipon; Cai-Yen Firestone; Christopher T Hanson; Brian R Murphy; Stephen S Whitehead
Journal:  Virology       Date:  2002-08-15       Impact factor: 3.616

9.  Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Authors:  Joseph E Blaney; Neeraj S Sathe; Laura Goddard; Christopher T Hanson; Tammy A Romero; Kathryn A Hanley; Brian R Murphy; Stephen S Whitehead
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

10.  A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys.

Authors:  Stephen S Whitehead; Barry Falgout; Kathryn A Hanley; Joseph E Blaney; Lewis Markoff; Brian R Murphy
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103
View more
  51 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Authors:  Stephen S Whitehead; Kanta Subbarao
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

3.  Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

Authors:  Alba Grifoni; Michael Angelo; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Jason Botten; Jonathan Boyson; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 4.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

5.  An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.

Authors:  Laura J White; Carlos A Sariol; Melissa D Mattocks; Wahala Wahala M P B; Vorraphun Yingsiwaphat; Martha L Collier; Jill Whitley; Rochelle Mikkelsen; Idia V Rodriguez; Melween I Martinez; Aravinda de Silva; Robert E Johnston
Journal:  J Virol       Date:  2013-01-09       Impact factor: 5.103

6.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

Review 7.  Nonhuman primate models of human viral infections.

Authors:  Jacob D Estes; Scott W Wong; Jason M Brenchley
Journal:  Nat Rev Immunol       Date:  2018-06       Impact factor: 53.106

8.  Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.

Authors:  Ge Liu; Langzhou Song; David W C Beasley; Robert Putnak; Jason Parent; John Misczak; Hong Li; Lucia Reiserova; Xiangyu Liu; Haijun Tian; Wenzhe Liu; Darlene Labonte; Lihua Duan; Youngsun Kim; Linda Travalent; Devin Wigington; Bruce Weaver; Lynda Tussey
Journal:  Clin Vaccine Immunol       Date:  2015-03-11

9.  Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.

Authors:  Scott A Smith; Ruklanthi de Alwis; Nurgun Kose; Anna P Durbin; Stephen S Whitehead; Aravinda M de Silva; James E Crowe
Journal:  J Infect Dis       Date:  2013-03-22       Impact factor: 5.226

10.  Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.

Authors:  Anna P Durbin; Sandra V Mayer; Shannan L Rossi; Irma Y Amaya-Larios; Jose Ramos-Castaneda; Eng Eong Ooi; M Jane Cardosa; Jorge L Munoz-Jordan; Robert B Tesh; William B Messer; Scott C Weaver; Nikos Vasilakis
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.